Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Organisation › Details

Sterna Biologicals GmbH & Co. KG

Sterna biologicals GmbH & Co. KG is an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and ulcerative colitis. By targeting transcription factors that play a central role in regulating Th1- and Th2-driven inflammatory mechanisms, the Company's proprietary DNAzyme-based drug candidates can intervene with key inflammatory processes to address related diseases more effectively. Sterna currently has four programs in phase 2 development. *


Period Start 2006-01-01 splitoff
  Group Sterna Biologicals (Genova) (Group)
  Predecessor University of Marburg (Philipps-Universität Marburg)
Products Industry drug development
  Industry 2 pharmaceutical
Persons Person Pangratz, Christian M. (Atriva Therapeutics 202301– CEO before Sterna Biologicals + Secarna + Vectura + Sykepharma)
  Person 2 Renz, Jonas (Secarna + Genova + Sterna Biologicals 201604 Managing Director)
Region Region Marburg
  Country Germany
  Street 7 Bismarckstr.
  City 35037 Marburg
  Tel +49-6421-9830050
    Address record changed: 2020-12-02
Basic data Employees A: 1 to 10 (2012-12-07)
    * Document for »About Section«: Sterna Biologicals GmbH & Co. KG. (5/26/20). "Press Release: Sterna Biologicals Secures EUR 12.0 Million (approx. USD 13.0 Million) in Private Placement". Marburg.
Record changed: 2023-12-30


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Sterna Biologicals (Genova) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px

» top